Ten-year survival in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Multiple myeloma is a cancer of plasma cells, often presenting with symptomatic disease.
• Long-term survival in multiple myeloma was historically limited, necessitating research into prognostic factors and treatment efficacy.

Purpose of the Study:

• To analyze the survival outcomes of patients with symptomatic multiple myeloma treated during a specific historical period (1965-1974).
• To identify factors associated with long-term survival in multiple myeloma.
• To compare survival rates before and after 1974, reflecting treatment advancements.

Main Methods:

• Retrospective analysis of 305 consecutive patients with symptomatic multiple myeloma.
• Data collection on patient demographics, disease stage, treatment response, and survival duration.
• Comparison of outcomes between patients treated before and after 1974.

Main Results:

• Only 4% of patients treated between 1965 and 1974 survived for ten years.
• Long-term survivors were predominantly younger (<65 years), had low or intermediate stage disease, and showed good chemotherapy response.
• Common features in survivors included prolonged remissions, slow tumor progression, and manageable relapses; acute leukemia was a cause of death in some.

Conclusions:

• Early-stage disease, younger age, and good chemotherapy response are critical for long-term survival in multiple myeloma.
• Improvements in supportive care and combination chemotherapy since 1974 have led to increased survival durations.
• Further research is needed to understand and mitigate late complications like acute leukemia in long-term multiple myeloma survivors.